Stockreport

Arcturus Therapeutics Reassumes Full Worldwide Rights to ARCT-810, a Clinical Development Candidate for Ornithine Transcarbamylase (OTC) Deficiency

Arcturus Therapeutics Holdings Inc.  (ARCT) 
Last arcturus therapeutics holdings inc. earnings: 3/11 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.arcturusrx.com/investor-relations
PDF SAN DIEGO, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the discovery, development and comme [Read more]